#Japan #Tokyo #Ajinomoto #RIBOMIC #AJICAP

Ajinomoto and RIBOMIC's Groundbreaking Research

In a remarkable collaborative effort, Ajinomoto Co., Inc. and RIBOMIC Inc. have successfully extended the pharmacokinetics of nucleic acid aptamers. This innovative research utilizes Ajinomoto's proprietary manufacturing technology known as AJICAP®, a method that aims to enhance the effectiveness of therapeutic drugs.

Background of the Joint Research

The partnership, first disclosed on December 27, 2023, has focused on the development of next-generation aptamer pharmaceuticals. Aptamers, which are short sequences of nucleic acids that can bind to specific targets, hold great promise in treating various medical conditions due to their unique properties. RIBOMIC, a startup specializing in aptamer drug development, has been at the forefront of this research, aiming to address unmet medical needs across several therapeutic areas.

Mechanism of Action: AJICAP® Technology

The crux of this partnership lies in the application of Ajinomoto's AJICAP® technology that enables the conjugation of nucleic acid aptamers with the Fc region of immunoglobulins. Immunoglobulins are vital components of the immune system, and their inclusion enhances the stability and retention of aptamers in the bloodstream.

By forming a conjugate that bonds nucleic acid aptamers with the Fc region, the researchers have effectively extended the half-life of these molecules in circulation. Analytical results have demonstrated that a binding ratio of 11 significantly improves their lifespan in the bloodstream, which has crucial implications for their therapeutic application.

Implications for Future Drug Development

The success of this research has broader implications for drug development. The adaptability of the AJICAP® technology allows for the creation of conjugates involving various bioactive molecules, potentially overcoming longstanding challenges in antibody drug efficacy, stability, and safety. This innovative approach promises a brighter future for antibody-drug conjugates (ADCs), expanding their utility beyond traditional applications.

This collaboration not only illustrates the potential of AJICAP® in ADC technology but also hints at its feasibility in diverse modalities of drug development. Ajinomoto and RIBOMIC are committed to offering unique solutions in their quest for enhancing therapeutic interventions across a range of diseases.

Conclusion

As both companies continue their groundbreaking work, the AJICAP® technology could redefine the landscape of nucleic acid-based therapeutics. With ongoing advancements in their joint research, Ajinomoto and RIBOMIC are poised to lead the charge in addressing pressing medical needs through innovative biotechnology solutions.

For more information on the future of aptamer pharmaceuticals and the implications of AJICAP®, visit Ajinomoto and RIBOMIC to stay updated on their latest developments.